Senator Dick Durbin, D-Illinois, a co-sponsor of the amendment, placed blame on pharmaceutical companies for using their influence to block the measure.
US lawmakers have been in a hurry this week to deliver the first set of 2019 appropriations bills to the President for approval. In an effort to deliver on a piece of the administration’s drug pricing blueprint, a bipartisan provision that would have required drug manufacturers to include list prices in direct-to-consumer television ads was expected to be included in the bill. The provision was subsequently blocked by House Republicans.
Senator Dick Durbin, D-Illinois, a co-sponsor of the amendment, placed blame on pharmaceutical companies for using their influence to block the measure. “For some reason, someone on the other side is trying to block this common sense, truly bipartisan policy. When are we going to stand up to Big Pharma and actually do something about sky high prescription drug prices? Transparency in advertising is the very least Congress can do,” said Durbin, as reported in Regulatory Focus.
Senator Chuck Grassley, R-Iowa, the other co-sponsor of the amendment, took to Twitter to announce his disappointment with the amendment’s exclusion, stating “It is EMBARRASSING to bow to BIG PHARMA at expense of consumers... If we can agree why are lobbyists fighting?”
Industry did indeed take issue with the amendment; the Pharmaceutical Research and Manufacturers of America(PhRMA) spoke out against the proposal in its July comments to HHS on the administration’s drug pricing blueprint, saying “FDA should not pursue any required disclose of list prices in direct-to-consumer pharmaceutical advertising. Such a requirement could confuse patients since the list price often does not represent what they would actually be required to pay.”
Exclusion of the amendment appears to counter public sentiment; a recent poll from the Kaiser Family Foundation found that nearly 76% of the public supports the inclusion of list prices in television ads.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.